Análisis de la Matriz ANSOFF de Myriad Genetics, Inc. (MYGN) [Actualizado en enero de 2025]

En el panorama en rápida evolución de la medicina de precisión, Myriad Genetics, Inc. está a la vanguardia de las estrategias de prueba genética transformadora. Al crear meticulosamente una matriz de Ansoff integral, la compañía traza un curso ambicioso a través de la penetración del mercado, el desarrollo, la innovación de productos y la diversificación estratégica. Este enfoque dinámico no solo promete revolucionar la detección genética y la atención médica personalizada, sino que también posiciona a la innumerable genética como una fuerza pionera para desbloquear el potencial intrincado de las ideas genéticas, ofreciendo un vistazo a un futuro donde los diagnósticos moleculares avanzados pueden rehapear fundamentalmente la atención del paciente y la comprensión médica.

Myriad Genetics, Inc. (Mygn) - Ansoff Matrix: Penetración del mercado

Expandir el volumen de pruebas genéticas en el mercado de oncología

Myriad Genetics reportó $ 629.4 millones en ingresos totales para el año fiscal 2022, con pruebas hereditarias de cáncer que representan una porción significativa.

Aumentar el compromiso de la fuerza de ventas

Myriad Genetics mantiene una fuerza de ventas directa de 187 representantes dirigidos a centros de oncología en todo el país.

• Cubrieron 2.345 proveedores de atención médica
• Relaciones establecidas con 612 centros de oncología
• Interacción promedio de ventas: 43 reuniones por representante mensual

Desarrollar modelos de precios estratégicos

Los precios de las pruebas genéticas actuales varían de $ 349 a $ 4,500 dependiendo de la complejidad.

Mejorar los programas de retención de clientes

Tasa de retención de clientes actual: 68.3% para clientes de pruebas genéticas.

• Implementados protocolos de seguimiento personalizados
• Programas de apoyo al paciente desarrollados
• Creó plataformas de compromiso de pacientes digitales

Marketing directo al consumidor para el examen hereditario del riesgo de cáncer

Inversión de marketing: $ 42.6 millones en 2022 para campañas directas al consumidor.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Desarrollo del mercado

Expandir el alcance geográfico a los mercados internacionales

Myriad Genetics reportó ingresos internacionales de $ 37.5 millones en el año fiscal 2022, lo que representa el 16.5% de los ingresos totales de la compañía. La penetración del mercado europeo aumentó en un 7,2% en el mismo período.

Apuntar a nuevos segmentos de atención médica

El tamaño del mercado de pruebas de fertilidad proyectadas para alcanzar los $ 1.2 mil millones para 2025. El segmento de salud reproductiva de Myriad creció un 12,4% en 2022.

• Mercado de clínicas de fertilidad: tasa de crecimiento anual del 18.3%
• Ingresos de pruebas de salud reproductiva: $ 45.6 millones

Desarrollar asociaciones con redes hospitalarias

La red de asociación actual incluye 237 sistemas hospitalarios. Los acuerdos de investigación colaborativos aumentaron en 15 en 2022.

Explore los mercados emergentes

Se espera que el mercado de medicina de precisión alcance los $ 196.2 mil millones a nivel mundial para 2026. Las inversiones del mercado emergente totalizaron $ 12.3 millones en 2022.

Adaptar las ofertas de pruebas genéticas

Inversiones de cumplimiento regulatorio de $ 8.7 millones en 2022. Obtuvo con éxito 14 nuevas certificaciones de atención médica regional.

• Gasto de cumplimiento regulatorio: $ 8.7 millones
• Nuevas certificaciones regionales: 14

Myriad Genetics, Inc. (Mygn) - Ansoff Matrix: Desarrollo de productos

Invierta en tecnologías de diagnóstico molecular avanzadas para la detección del cáncer

En 2022, Myriad Genetics invirtió $ 78.3 millones en I + D para tecnologías de diagnóstico molecular avanzadas. La cartera de detección de cáncer genético de la compañía generó $ 342.5 millones en ingresos.

Desarrollar nuevos paneles genéticos dirigidos a trastornos genéticos raros

Myriad desarrolló 7 nuevos paneles genéticos para trastornos raros en 2022, cubriendo aproximadamente 150 condiciones genéticas únicas.

• Costo de desarrollo del panel de trastorno raro: $ 12.6 millones
• Tamaño estimado del mercado para pruebas de trastorno genético raro: $ 475 millones
• Número de nuevas condiciones genéticas identificadas: 38

Crear soluciones de medicina personalizada que integren ideas genéticas

Las soluciones de medicina personalizada generaron $ 214.7 millones en ingresos para Myriad en 2022.

Mejorar las capacidades bioinformáticas

Myriad invirtió $ 56.4 millones en infraestructura bioinformática en 2022, procesando más de 1,2 millones de pruebas genéticas.

• Velocidad de análisis computacional: 15,000 perfiles genéticos por día
• Precisión del algoritmo de aprendizaje automático: 94.7%
• Capacidad de almacenamiento de datos: 3.8 petabytes

Expandir las pruebas farmacogenómicas

Las pruebas farmacogenómicas se expandieron para cubrir 62 categorías de medicamentos diferentes en 2022.

Myriad Genetics, Inc. (Mygn) - Ansoff Matrix: Diversificación

Adquisiciones estratégicas en dominios de tecnología genética complementaria

En 2019, Myriad Genetics adquirió Assurex Health por $ 225 millones, ampliando su cartera de medicamentos de precisión. La compañía reportó $ 874.2 millones en ingresos totales para el año fiscal 2022.

Plataformas de salud digitales que integran datos genéticos y conocimientos de pacientes

Myriad invirtió $ 86.4 millones en investigación y desarrollo en 2022, centrándose en el desarrollo de la plataforma digital.

• La plataforma de cáncer hereditario de MyRisk cubre 11 tipos de cáncer
• La base de datos de pruebas genéticas contiene más de 5 millones de registros de pacientes

Herramientas de evaluación de riesgos genéticos predictivos impulsados ​​por IA

La compañía asignó el 13.4% de sus ingresos totales a la investigación y el desarrollo en 2022.

Soluciones de pruebas genéticas para especialidades médicas emergentes

Myriad amplió los servicios de pruebas genéticas en múltiples especialidades médicas, generando $ 874.2 millones en ingresos de 2022.

• Oncology Genetic Testing Market participación: 25%
• Pruebas genéticas de salud reproductiva: ingresos por segmento de $ 310 millones

Servicios educativos y de consultoría para la interpretación de pruebas genéticas

Myriad desarrolló servicios integrales de asesoramiento genético con 150 asesores genéticos certificados en el personal.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Penetration

Drive GeneSight test volume growth by 20% in the US.

For the third quarter of 2025, GeneSight test volume grew 8% year-over-year. This reflects ongoing improvement from the second quarter of 2025, where GeneSight test volume growth was 5% year-over-year. This growth follows the impact of UnitedHealthcare's discontinuation of coverage effective in the first quarter of 2025.

Increase myRisk hereditary cancer test adoption in underserved US populations.

Hereditary cancer testing volume for the unaffected population increased 11% year-over-year in the third quarter of 2025. In the second quarter of 2025, MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. A recent survey indicated that 37% of women surveyed believe genetic testing can help manage breast health, yet only 14% of respondents reported having undergone genetic testing.

Secure broader payer coverage for Prolaris prostate cancer test in regional plans.

Historically, Prolaris achieved insurance coverage for approximately 50 percent of Prostate cancer patients in the United States, later increasing to cover more than 55 percent of eligible patients. The company continues working with remaining private health insurers to expand access.

Expand telehealth integration to simplify physician ordering and patient access.

Myriad Genetics' full oncology portfolio of germline and tumor genomic tests is expected to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later this year in 2025. The company offers electronic medical record (EMR) integration to help providers order tests and access results directly within their daily platforms. The partnership with Epic aims to scale tech-enabled commercial capabilities.

Offer bundled testing options to increase average revenue per patient.

In the second quarter of 2025, gross margin benefited from improving average revenue per test trends. However, the first quarter of 2025 saw a year-over-year decrease in the average revenue per hereditary cancer test, largely due to a difference in the change in estimated revenue related to prior periods.

Here's a quick look at recent operational metrics:

The company's strategy involves several key areas to drive penetration:

• Use of EMR solutions for breast cancer risk assessment programs.
• Launching an expanded gene panel for the MyRisk Hereditary Cancer Test later in 2025.
• Entering a collaboration with SOPHiA GENETICS for CDx development services.
• Anticipating the commercial launch of the Precise MRD assay in 2026.
• Planning the launch of the Prolaris test with PATHOMIQ's AI technology in early 2026.

Finance: review the impact of the new $200 million credit facility on Q4 2025 interest expense by Thursday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Development

Accelerate GeneSight launch and reimbursement efforts across major European markets. The Pharmacogenomics revenue segment saw a 20% year-over-year decline in the first quarter of 2025, directly attributed to UnitedHealthcare reducing coverage for GeneSight®.

Establish strategic distribution partnerships in Japan and South Korea for myRisk. Myriad International Offices currently list a presence in Japan as Myriad Genetics G.K..

Target international revenue to reach 15% of total revenue within two years.

Obtain regulatory approvals for Foresight carrier screening in Canada and Australia. The Foresight® Carrier Screen was included in research studies presented at the National Society of Genetic Counselors Annual Conference in November 2025.

Focus sales teams on large, integrated health systems outside the US. The company completed the sale of its international EndoPredict business in August 2024.

Here's the quick math on how the core business performed in 2025, which sets the stage for international focus:

The Hereditary Cancer testing volume in the third quarter of 2025 increased 11% year-over-year, which includes myRisk testing.

The company is working on several product launches that could impact future international market entry:

• AI-enabled Prolaris test targeted for year-end 2025.
• PRECISE MRD targeted for a first-half 2026 launch.
• Commercially launching FirstGene Multiple Prenatal Screen in 2026.

The overall 2025 revenue guidance range was revised to between $807 million and $823 million after the first quarter.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Product Development

You're looking at how Myriad Genetics, Inc. (MYGN) plans to grow by launching new products into existing markets, which is the Product Development quadrant of the Ansoff Matrix. We need to ground this in the numbers they've reported through the third quarter of 2025.

For the commitment to innovation, while the target of $100 million annually in R&D isn't explicitly confirmed in the latest filings, we see the trend. Research and development expense for the full year ended December 31, 2024, increased by $24.7 million compared to the prior year, driven by investments in new products like the MRD test. This investment focus continued into 2025; for instance, Q1 2025 adjusted operating expenses of $140.6 million reflected maintaining investments in key strategic areas, including research and development. This shows the ongoing financial commitment to pipeline advancement.

The next-generation version of myRisk Hereditary Cancer Test saw a significant upgrade as of November 10, 2025. The panel expanded to 63 genes, covering more than 11 cancer types. This update means the test now includes 100% of genes strongly recommended by national oncology guidelines like NCCN and ASCO. This enhancement was achieved by adding 15 newly added guideline-recommended genes and 36 evidence-based intronic variants.

Here's a snapshot of the myRisk expansion:

In prostate cancer diagnostics, Myriad Genetics, Inc. is integrating artificial intelligence (AI) into the Prolaris test. The plan is to launch the first AI-driven prostate cancer clinical test, which integrates PATHOMIQ's AI technology, later in 2025 (with some forward-looking statements suggesting early 2026). This AI platform analyzes digitized H&E whole slide images to predict disease recurrence after initial therapy. The technology is designed to deliver results within 1-2 days after receiving digital patient samples. The collaboration aims to accelerate achieving Simon level 1 evidence for both the Prolaris and the AI component. Prolaris testing revenue itself showed growth of 3% year-over-year in the third quarter of 2025.

Regarding companion diagnostics for oncology drugs, Myriad Genetics, Inc. announced a strategic collaboration on September 23, 2025, with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the US to support clinical trials testing. The initial focus is on the MSK-ACCESS® powered with SOPHiA DDM™ liquid biopsy application. SOPHiA GENETICS supports global deployment through a network of more than 800 connected institutions across over 70 countries.

The development pipeline also includes other areas, though specific financial or launch metrics for a new mental health screening test weren't detailed in the latest reports. However, other product lines show activity, such as the Pharmacogenomics segment revenue declining by 20% in Q1 2025 and (19)% in Q3 2025, signaling a need for new product introductions in that space to offset coverage headwinds, like the UnitedHealthcare reduction. The Prenatal segment, conversely, showed strength, with revenue growing 11% in Q1 2025.

Here are the revenue performance indicators for context on where new products need to drive growth:

• Q3 2025 Hereditary Cancer Revenue: $81.8 million (up 2% year-over-year).
• Q3 2025 Hereditary Cancer Volume: Increased 9% year-over-year.
• Q1 2025 Pharmacogenomics Revenue: $31.0 million (down 20% year-over-year).
• Q2 2025 Hereditary Cancer Volume (Oncology): Grew 10% year-over-year.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Diversification

You're looking at how Myriad Genetics, Inc. (MYGN) can push beyond its core genetic testing base, which is smart given the competitive landscape. Diversification here means moving into new markets or offering new services, which is where the real upside often hides. We are mapping potential moves against a contextual revenue scale of $700 million, aiming for $50 million in new contribution from these efforts.

For context on M&A as a diversification tool, look at past moves. The acquisition of Assurex Health in 2016 was for an upfront cost of $225 million, with potential performance-based milestones reaching $185 million. Assurex generated over $60 million in revenue in Myriad Genetics, Inc.'s fiscal year 2016. More recently, the Counsyl, Inc. acquisition in 2018 was valued at $375 million, which immediately positioned Myriad Genetics, Inc. as a premier Women's Health organization.

Entering the direct-to-consumer (DTC) wellness market with a new, non-diagnostic service is a classic diversification play. Myriad Genetics, Inc. has experience here through the acquisition of Gateway Genomics for $67.5 million, which brought the SneakPeek® Early Gender DNA Test. That test had shown a compound annual growth rate exceeding 20% over the three years prior to the acquisition. This shows a path to scaling a non-diagnostic, consumer-facing offering quickly.

For clinical trial services, Myriad Genetics, Inc. already has deep regulatory experience across the United States, Europe, and Japan. A recent, concrete step is the strategic collaboration announced in September 2025 with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) test. This partnership leverages Myriad Genetics, Inc.'s advanced U.S. laboratory capabilities to support global testing for clinical trials, while SOPHiA GENETICS manages regulatory submissions outside the U.S. This is a tangible move into expanding biopharma services globally.

Developing a new platform for infectious disease monitoring, a new market, is aggressive. While specific infectious disease platform details aren't immediately clear, Myriad Genetics, Inc. is actively developing its Minimal Residual Disease (MRD) testing platform, which is tumor-informed and uses whole-genome sequencing. This platform tracks up to thousands of variants, which is significantly more sensitive than the 50 or fewer variants monitored by most current MRD tests. The Precise MRD assay is planned for a controlled early access launch in 2026. This demonstrates capability in developing entirely new, high-tech platforms for new clinical questions.

To hit the required revenue targets, you need to see where the current business stands against the goal. Full-year 2024 revenue was approximately $838 million, and the reaffirmed 2025 guidance is between $818 million and $828 million. Still, the diversification goal is framed against a $700 million scale. Here's the quick math on how the $50 million target fits into the current business mix, using the 2025 guidance midpoint of $823 million for comparison, even though the prompt specified $700 million as the base for the target.

Achieving the $50 million from new streams means that, relative to the $700 million context, diversification needs to account for approximately 7.14% of that revenue base. The actual revenue base in 2024 was higher at $837.60 million, meaning the actual required percentage of the actual revenue would be closer to 5.97% (50 / 837.60). What this estimate hides is the required investment spend to generate that $50 million, which could impact near-term profitability, as seen by the Q3 2025 adjusted EPS of $0.00.

These diversification avenues require specific execution focus:

• Acquisition: Due diligence on cardiology market size and integration costs.
• DTC Wellness: Scaling digital marketing spend to capture the 4 million annual SneakPeek website visitors.
• Pharma Partnership: Securing 10 companion diagnostic approvals in the U.S. and Japan as a benchmark.
• New Platform: Successfully transitioning the Precise MRD assay from research evaluation to commercial use in 2026.

Finance: draft 13-week cash view by Friday.